Aarey Drugs Q1 FY27 results: Revenue drops 56 percent, PAT at Rs 102.37 lakh
AAREYDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarey Drugs & Pharma reported Q1 FY27 (ended Jun 30, 2026) unaudited results. Revenue from operations fell sharply to Rs 4,462.55 lakh from Rs 10,220.83 lakh in Q1 FY26, an around 56 percent decline. Total income was Rs 4,634.05 lakh. Profit before tax was Rs 51.56 lakh versus Rs 172.82 lakh. PAT came in at Rs 102.37 lakh (EPS Rs 0.36) versus Rs 137.13 lakh (EPS Rs 0.48). Auditor Motilal and Associates issued an unqualified review report. No deviation reported in use of warrant issue funds during the quarter.
Sharp revenue drop signals weak quarter. PAT also fell. Watch for recovery in coming quarters.